116 related articles for article (PubMed ID: 23078524)
1. ETV6 disruption does not predict indolent clinical behavior in secretory breast carcinoma.
Wong M; Jara-Lazaro AR; Hui Ng RC; Tiong Lim AS; Cheok PY; Lim TH; Tan PH; Wong NS
Breast J; 2012; 18(6):604-6. PubMed ID: 23078524
[No Abstract] [Full Text] [Related]
2. The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma.
Chiosea SI; Griffith C; Assaad A; Seethala RR
Am J Surg Pathol; 2012 Mar; 36(3):343-50. PubMed ID: 22301503
[TBL] [Abstract][Full Text] [Related]
3. ETV6 gene rearrangements in invasive breast carcinoma.
Letessier A; Ginestier C; Charafe-Jauffret E; Cervera N; Adélaïde J; Gelsi-Boyer V; Ahomadegbe JC; Benard J; Jacquemier J; Birnbaum D; Chaffanet M
Genes Chromosomes Cancer; 2005 Sep; 44(1):103-8. PubMed ID: 15887243
[TBL] [Abstract][Full Text] [Related]
4. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion.
Ito Y; Ishibashi K; Masaki A; Fujii K; Fujiyoshi Y; Hattori H; Kawakita D; Matsumoto M; Miyabe S; Shimozato K; Nagao T; Inagaki H
Am J Surg Pathol; 2015 May; 39(5):602-10. PubMed ID: 25651470
[TBL] [Abstract][Full Text] [Related]
5. De-escalating systemic therapy in triple negative breast cancer: The example of secretory carcinoma.
Benabu JC; Stoll F; Koch A; Molière S; Bellocq JP; Mathelin C
J Gynecol Obstet Hum Reprod; 2018 Apr; 47(4):163-165. PubMed ID: 29409947
[TBL] [Abstract][Full Text] [Related]
6. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity.
Connor A; Perez-Ordoñez B; Shago M; Skálová A; Weinreb I
Am J Surg Pathol; 2012 Jan; 36(1):27-34. PubMed ID: 21989350
[TBL] [Abstract][Full Text] [Related]
7. Secretory carcinoma of the breast: a genetically defined carcinoma entity.
Diallo R; Tognon C; Knezevich SR; Sorensen P; Poremba C
Verh Dtsch Ges Pathol; 2003; 87():193-203. PubMed ID: 16888913
[TBL] [Abstract][Full Text] [Related]
8. Mammary analogue secretory carcinoma: the first submandibular case reported including findings on fine needle aspiration cytology.
Petersson F; Lian D; Chau YP; Yan B
Head Neck Pathol; 2012 Mar; 6(1):135-9. PubMed ID: 21773954
[TBL] [Abstract][Full Text] [Related]
9. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.
Del Castillo M; Chibon F; Arnould L; Croce S; Ribeiro A; Perot G; Hostein I; Geha S; Bozon C; Garnier A; Lae M; Vincent-Salomon A; MacGrogan G
Am J Surg Pathol; 2015 Nov; 39(11):1458-67. PubMed ID: 26291510
[TBL] [Abstract][Full Text] [Related]
10. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
11. Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review.
Lian J; Wang LX; Guo JH; Bu P; Xi YF; Yun KM
Diagn Pathol; 2021 Oct; 16(1):89. PubMed ID: 34629079
[TBL] [Abstract][Full Text] [Related]
12. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
Harrison BT; Fowler E; Krings G; Chen YY; Bean GR; Vincent-Salomon A; Fuhrmann L; Barnick SE; Chen B; Hosfield EM; Hornick JL; Schnitt SJ
Am J Surg Pathol; 2019 Dec; 43(12):1693-1700. PubMed ID: 31498178
[TBL] [Abstract][Full Text] [Related]
13. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.
Makretsov N; He M; Hayes M; Chia S; Horsman DE; Sorensen PH; Huntsman DG
Genes Chromosomes Cancer; 2004 Jun; 40(2):152-7. PubMed ID: 15101049
[TBL] [Abstract][Full Text] [Related]
14. Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.
Reis-Filho JS; Natrajan R; Vatcheva R; Lambros MB; Marchió C; Mahler-Araújo B; Paish C; Hodi Z; Eusebi V; Ellis IO
Histopathology; 2008 Jun; 52(7):840-6. PubMed ID: 18462362
[TBL] [Abstract][Full Text] [Related]
15. B lymphoblastic leukemia with ETV6 amplification.
Chae H; Kim M; Lim J; Kim Y; Han K; Lee S
Cancer Genet Cytogenet; 2010 Dec; 203(2):284-7. PubMed ID: 21156245
[TBL] [Abstract][Full Text] [Related]
16. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the ETV6 gene as a consequence of a rare translocation (12;12)(p13;q13) in treatment-induced acute myeloid leukemia after breast cancer.
Manola KN; Georgakakos VN; Margaritis D; Stavropoulou C; Panos C; Kotsianidis I; Pantelias GE; Sambani C
Cancer Genet Cytogenet; 2008 Jan; 180(1):37-42. PubMed ID: 18068531
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer bone metastasis: molecular basis of tissue tropism.
Kang Y
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):379-80. PubMed ID: 15758269
[No Abstract] [Full Text] [Related]
19. Native ETV6 deletions accompanied by ETV6-RUNX1 rearrangements are associated with a favourable prognosis in childhood acute lymphoblastic leukaemia: a candidate for prognostic marker.
Ko DH; Jeon Y; Kang HJ; Park KD; Shin HY; Kim HK; Cho HI; Ahn HS; Lee DS
Br J Haematol; 2011 Nov; 155(4):530-3. PubMed ID: 21569007
[No Abstract] [Full Text] [Related]
20. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
